Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Earlier in 2019 Sanofi also paid Regeneron $462 million to exit from an immuno-oncology alliance formed in 2015, and in 2017 said they would end discovery research in new antibody drugs.

Sanofi and Regeneron acknowledged that testing their inflammatory disease blockbuster Dupixent in chronic obstructive pulmonary disease (COPD) was likely to be high-risk when they launched phase 3 ...

US Services’ rilzabrutinib orphan designation as a treatment of immunoglobulin G4-related disease, according to a ...

Sanofi has returned to Nurix Therapeutics for another autoimmune candidate, paying $15 million and committing up to $465 million for exclusive rights to a degrader of a once-undruggable ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other most profitable biotech stocks to buy right now. With improved market ...

Initiations increased from 8% to 38% for dupilumab (Dupixent; Sanofi, Regeneron) and from less than 0.5% to 29% for tezepelumab (Tezspire; Amgen, AstraZeneca). Between the second halves of 2022 ...

Sanofi (Nasdaq: SNY) with We Are ILL, Inc., visits the Nasdaq MarketSite in Times Square. A patient advocacy organization, We Are ILL redefines what “sick” looks like by making the multiple ...

Sanofi/Regeneron). “We’re looking at tezepelumab-ekko, and we’re comparing it to the other biologic classes [anti-IL5/IL5R and dupilumab] to see if there were differences in outcomes ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Ministry of Health, Labour and TARRYTOWN, N.Y., March 25, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals ...

Regeneron Pharmaceuticals Inc REGN raises some concerns due to its significant presence in Ireland. If tariffs are applied, they would likely increase the cost of goods sold since companies often ...